8. Characteristics of infections in patients with systemic lupus erythematosus

Tran Thi Mui, Nguyen Hoang Phuong, Nguyen Van Doan, Vu Thi Hang

Main Article Content

Abstract

Introduction: Infections remain one of the leading causes of the death in systemic lupus erythematosus (SLE). The aims: To evaluate the infection status in patiens with SLE. Method: The prospective, cross sectional study was conducted in 1282 patients with SLE at the Center of Allergy and Clinical Immunology, Bach Mai Hospital for 1 year (from June 1, 2018 to May 31, 2019). Results: Among the patients studied, 220 patients (17.16%) sufferd from infection. Localized infections were the majority at 84.55% (the respiratory was the most orrgan effected by infection, with 37.30%). There was septic in 11.36%, septic shock in 4.09% of cases. CRPhs level increased in only 10% of patients, while procalcitonin level increased in 52.7% of cases. The majority of bacteria found in infections were Staphylococcus aureus in 39.10%, Bacillius species in 17.40%, and tuberculosis in only 4.30%. The majority of patients were treated with corticosteroids in 86.36%, HCQ in 69.5%. The average corticosteroid dose over 7.5 mg/day before 1 month of admission to the hospital was in 66.40% of cases. Conclusions: The respiratory tract infection was the most of organ infetion in SLE, staphylococcus aureus was common etiology. Drugs and dose of corticosteroid associated of infectious processes.

Article Details

References

1. Al-Rayes H, Al-Swailem R, Arfin M, et al. Systemic lupus erythematosus and infections: a retrospective study in Saudis. Lupus. 2007;16(9):755-763. doi:10.1177/0961203307079943
2. Esposito S, Bosis S, Semino M, et al. Infections and systemic lupus erythematosus. Infection and Autoimmunity. Published online 2015:697-714.
3. Nguyễn Văn Đoàn. Một số bệnh nhiễm trùng thường gặp trên bệnh nhân lupus ban đỏ hệ thống. Tạp chí Y học thực hành. 2012;807:49-51.
4. Batu ED, Akca UK, Kısaarslan AP, et al. The Performances of the ACR 1997, SLICC 2012, and EULAR/ACR 2019 Classification Criteria in Pediatric Systemic Lupus Erythematosus. The Journal of Rheumatology. 2021;48(6):907-914. doi:10.3899/jrheum.200871
5. Control C for D, Prevention. National Healthcare Safety Network (NHSN) patient safety component manual. Atlanta: CDC. Published online 2018.
6. Teh C, Ling G. Causes and predictors of mortality in hospitalized lupus patient in Sarawak General Hospital, Malaysia. Lupus. 2013;22(1):106-111. doi:10.1177/0961203312465780
7. Jung JY, Yoon D, Choi Y, et al. Associated clinical factors for serious infections in patients with systemic lupus erythematosus. Sci Rep. 2019;9(1):9704. doi:10.1038/s41598-019-46039-5
8. Massaro KS, Costa SF, Leone C, et al. Procalcitonin (PCT) and C-reactive Protein (CRP) as severe systemic infection markers in febrile neutropenic adults. BMC Infect Dis. 2007;7(1):137. doi:10.1186/1471-2334-7-137
9. Kim HA, Jeon JY, An JM, et al. C-reactive protein is a more sensitive and specific marker for diagnosing bacterial infections in systemic lupus erythematosus compared to S100A8/A9 and procalcitonin. The Journal of rheumatology. 2012;39(4):728-734.
10. Lertchaisataporn K, Kasitanon N, Wangkaew S, et al. An evaluation of the association of leukopenia and severe infection in patients with systemic lupus erythematosus. JCR: Journal of Clinical Rheumatology. 2013;19(3):115-120.
11. Teh CL, Wan SA, Ling GR. Severe infections in systemic lupus erythematosus: disease pattern and predictors of infection-related mortality. Clin Rheumatol. 2018;37(8):2081-2086. doi:10.1007/s10067-018-4102-6
12. Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, et al. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther. 2009;11(4):R109. doi:10.1186/ar2764
13. Bosch X, Guilabert A, Pallarés L, et al. Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus. 2006;15(9):584-589. doi:10.1177/0961203306071919
14. Zandman-Goddard G, Shoenfeld Y. SLE and infections. Clinic Rev Allerg Immunol. 2003;25(1):29-39. doi:10.1385/CRIAI:25:1:29
15. Frodlund M, Jönsen A, Remkus L, et al. Glucocorticoid treatment in SLE is associated with infections, comorbidities and mortality-a national cohort study. Rheumatology. 2024;63(4):1104-1112. doi:10.1093/rheumatolo gy/kead348
16. González-Echavarri C, Capdevila O, Espinosa G, et al. Infections in newly diagnosed Spanish patients with systemic lupus erythematosus: data from the RELES cohort. Lupus. 2018;27(14):2253-2261. doi:10.1177/0961203318811598